奥希替尼的心脏安全性:数据综述
本文通过FLAURA、AURA3的事后分析及奥希替尼80 mg pooled数据集(n=1,142),评估奥希替尼治疗患者的心力衰竭风险与左心室射血分数(LVEF)下降情况。结果显示LVEF下降事件少见且多为无症状,药代/药效分析未见暴露与LVEF下降相关,数据库与文献检索未见提示安全性问题的趋势,但建议对有心脏危险因素者进行基线与治疗中LVEF监测。
要点
- 奥希替尼治疗后LVEF下降少见,多为无症状且可自行缓解。
- 药代/药效分析未提示奥希替尼暴露与LVEF下降相关。
- 建议有心脏危险因素者基线与治疗中监测LVEF。
核心结论
- 现有数据不支持奥希替尼与心力衰竭之间存在因果关系。
- 因治疗前存在心脏危险因素的患者中观察到LVEF下降,仍建议进行心脏监测。
研究设计与样本
- 对FLAURA研究(奥希替尼n=279;对照EGFR-TKI n=277)进行心脏数据事后分析。
- 对AURA3研究(奥希替尼n=279;化疗n=140)进行心脏数据事后分析。
- 对临床试验项目中接受奥希替尼80 mg治疗患者的pooled数据集(n=1,142)进行分析。
- 对pooled数据集进行LVEF的药代动力学或药效学分析。
- 分析申办方全球安全性数据库中心力衰竭相关不良事件并进行文献检索。
主要发现
- FLAURA中8例(3.1%)患者出现LVEF自基线下降≥10个百分点且绝对值<50%。
- AURA3中14例(5.5%)患者出现上述LVEF下降。
- pooled人群中35例(3.9%)患者出现上述LVEF下降。
- 多数事件无症状,未针对事件治疗或停用奥希替尼即缓解。
- 药代动力学或药效学分析未提示奥希替尼暴露与LVEF自基线下降存在关系。
临床怎么用
- 对接受奥希替尼治疗的患者,尤其治疗前存在心脏危险因素者,建议进行心脏监测。
- 监测内容包括基线及奥希替尼治疗期间的LVEF评估。
局限性
- 本文为事后分析与pooled数据及数据库、文献检索,非前瞻性心脏安全性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Osimertinib is a third-generation, CNS-active, irreversible, oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that potently and selectively inhibits both EGFR-TKI-sensitizing and T790M resistance mutations. We assess the cardiac failure risk in patients receiving osimertinib by evaluating the available data. METHODS: Post hoc analyses of cardiac data from (1) studies in patients with advanced non-small-cell lung cancer, FLAURA (osimertinib, n = 279; comparator EGFR-TKI, n = 277) and AURA3 (osimertinib, n = 279; chemotherapy, n = 140), and (2) a pooled data set of patients treated with osimertinib 80 mg from across the clinical trial program (n = 1,142), including cardiac failure-related adverse events and left ventricular ejection fraction (LVEF) reductions. An LVEF pharmacokinetic or pharmacodynamic analysis of the pooled data set was performed. The sponsor's global safety database was analyzed for cardiac failure-related adverse events, and a literature search was conducted. RESULTS: Decreases in LVEF from a baseline of ≥ 10 percentage points to an absolute value of < 50% following osimertinib treatment were observed in 8 (3.1%) and 14 (5.5%) patients in FLAURA and AURA3, respectively, and in 35 (3.9%) patients in the pooled population. Most events were asymptomatic and resolved without treatment of the event or osimertinib discontinuation. The pharmacokinetic or pharmacodynamic analysis did not indicate a relationship between exposure to osimertinib and decreases in LVEF from baseline. The database and literature search showed no specific trend or pattern that was suggestive of a safety issue in patients receiving osimertinib. CONCLUSION: These data do not suggest a causal relationship between osimertinib and cardiac failure. However, because of LVEF decreases that were observed in patients with cardiac risk factors before osimertinib treatment, cardiac monitoring, including an assessment of LVEF at baseline and during osimertinib treatment, is advised.
引用
- Ewer MS, Tekumalla SH, Walding A, et al. Cardiac Safety of Osimertinib: A Review of Data. J Clin Oncol. 2020. PMID: 33356419. doi:10.1200/JCO.20.01171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。